Qualified protein degradation is remaining explored as a substitute strategy in cancer, whereby the pure protein degradation method is co-opted for therapeutic uses. A short while ago formulated novel molecules called proteolysis-targeting chimeras (PROTACs) are heterobifunctional molecules with two ligands joined by a linker. 1 ligand binds into the ‘protein https://www.directivepublications.org/journal-of-clinical-breast-cancer/